Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is scheduled to hold a conference call on May 12, 2022, at 5:00 p.m. (EDT), to discuss its first quarter financial results and corporate developments. The call will feature Dr. Michael Rosol and Erika Eves, who will provide insights on financial performance and clinical progress. Investors can access the call via a web link and will have the opportunity to ask questions following the announcement. The company aims to enhance patient care through its innovative Manocept™ platform.
- Upcoming conference call to discuss first quarter 2022 financial results and corporate developments
- Focus on precision immunodiagnostic agents and immunotherapeutics through the Manocept™ platform
- None.
Conference Call to be Held on
Dr.
To participate in the call and webcast, please refer to the information below:
Event: First Quarter 2022 Earnings Conference Call and Business Update
Date:
Time:
International Dial-In: +1 713-481-1320
Conference ID: 512400
Webcast Link: https://www.webcast-eqs.com/navidbioph20220512/en
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
About Navidea
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other
Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005249/en/
Investor Relations Contact
Vice President of Operations
614-822-2365
jsmith@navidea.com
Source:
FAQ
When will Navidea Biopharmaceuticals hold its conference call?
What will be discussed during the Navidea conference call?
Who will host the Navidea conference call?
How can I participate in the Navidea conference call?